Mineral-enriched deep-sea water inhibits the metastatic potential of human breast cancer cell lines

International Journal of Oncology

Volumn 43, Issue 5, 2013, Pages 1691-1700

  Kim, Soyoung ^a   Chun, So Young ^a   Lee, Do Hyung ^a   Lee, Kyu Shik ^a   Nam, Kyung Soo ^a  

^a Dongguk University College of Medicine   (South Korea)

Author keywords

Deep sea water; Human breast cancer cells; Matrix metalloproteinase 9; Metastasis; Transforming growth factor ; Wnt5a

Indexed keywords

BETA ACTIN; CALCIUM; GELATINASE A; GELATINASE B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MAGNESIUM; MINERAL; PHORBOL 13 ACETATE 12 MYRISTATE; SEA WATER; TRANSFORMING GROWTH FACTOR BETA; UROKINASE; UROKINASE RECEPTOR; WNT3A PROTEIN; WNT5A PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CELL MIGRATION; CELL STRAIN MCF 7; DEEP SEA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; METASTASIS INHIBITION; METASTASIS POTENTIAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; TUMOR INVASION; WOUND HEALING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL MOVEMENT; FEMALE; FLOW CYTOMETRY; HUMANS; MATRIX METALLOPROTEINASE 9; MINERAL WATERS; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEAWATER; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; WNT PROTEINS; WOUND HEALING;

EID: 84885060728     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2089     Document Type: Article

References (49)

1. Nakasone T and Akeda S: The application of deep sea water in Japan. UJNR Technical Report 28: 69-75, 1999.
2. Shon YH, Kim JS and Nam KS: Inhibitory effect of Deep-sea water on cytochrome P450 1A1, aromatase, and MMP-9. J Life Sci 18: 503-508, 2008.
3. Hwang HS, Kim SH, Yoo YG, et al: Inhibitory effect of deep-sea water on differentiation of 3T3-L1 adipocytes. Mar Biotechnol (NY) 11: 161-168, 2009.
4. Radhakrishnan G, Yamamoto M, Maeda H, et al: Intake of dissolved organic matter from deep seawater inhibits atherosclerosis progression. Biochem Biophys Res Commun 387: 25-30, 2009.
5. Lee KS, Shin JS, Kwon YS, Moon DS and Nam KS: Suppression of cancer progression and metastasis in HT-29 human colorectal adenocarcinoma by deep sea water. Biotechnol Bioproc Eng 18: 194-200, 2013.
6. Kohli GS, Bhargava A, Goel H, et al: Serum magnesium levels in patients with head and neck cancer. Magnesium 8: 77-86, 1989.
7. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR and Heaney RP: Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 85: 1586-1591, 2007.
8. Nasulewicz A, Wietrzyk J, Wolf FI, et al: Magnesium deficiency inhibits primary tumor growth but favors metastasis in mice. Biochim Biophys Acta 1739: 26-32, 2004.
9. Sartori S, Nielsen I, Tassinari D, et al: Serum and erythrocyte magnesium concentrations in solid tumours: relationship with stage of malignancy. Magnes Res 5: 189-192, 1992.
10. Wu K, Willett WC, Fuchs CS, Colditz GA and Giovannucci EL: Calcium intake and risk of colon cancer in women and men. J Natl Cancer Inst 94: 437-446, 2002.
11. Gamucci T, D'Ottavio AM, Magnolfi E, et al: Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer. Br J Cancer 97: 1040-1045, 2007.
12. Padua D and Massague J: Roles of TGFbeta in metastasis. Cell Res 19: 89-102, 2009.
13. Shariat SF, Shalev M, Menesses-Diaz A, et al: Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 19: 2856-2864, 2001.
14. Tsushima H, Ito N, Tamura S, et al: Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res 7: 1258-1262, 2001.
15. Yang YA, Dukhanina O, Tang B, et al: Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109: 1607-1615, 2002.
16. Yin JJ, Selander K, Chirgwin JM, et al: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103: 197-206, 1999.
17. Howe LR and Brown AM: Wnt signaling and breast cancer. Cancer Biol Ther 3: 36-41, 2004.
18. Katoh M: Transcriptional mechanisms of WNT5A based on NF-kappaB, Hedgehog, TGFbeta, and Notch signaling cascades. Int J Mol Med 23: 763-769, 2009.
19. Lejeune S, Huguet EL, Hamby A, Poulsom R and Harris AL: Wnt5a cloning, expression, and up-regulation in human primary breast cancers. Clin Cancer Res 1: 215-222, 1995.
20. Smith K, Bui TD, Poulsom R, Kaklamanis L, Williams G and Harris AL: Up-regulation of macrophage wnt gene expression in adenoma-carcinoma progression of human colorectal cancer. Br J Cancer 81: 496-502, 1999.
21. Bittner M, Meltzer P, Chen Y, et al: Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406: 536-540, 2000.
22. Weeraratna AT, Jiang Y, Hostetter G, et al: Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1: 279-288, 2002.
23. Dissanayake SK, Wade M, Johnson CE, et al: The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem 282: 17259-17271, 2007.
24. Dietrich A, Tanczos E, Vanscheidt W, Schopf E and Simon JC: High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival. Eur J Cancer 33: 926-930, 1997.
25. O'Connell MP, Fiori JL, Xu M, et al: The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene 29: 34-44, 2010.
26. Nabeshima K, Inoue T, Shimao Y and Sameshima T: Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 52: 255-264, 2002.
27. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H and Itohara S: Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58: 1048-1051, 1998.
28. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
29. Subramaniam DS and Isaacs C: Utilizing prognostic and predictive factors in breast cancer. Curr Treat Options Oncol 6: 147-159, 2005.
30. Klemm F, Bleckmann A, Siam L, et al: beta-catenin-independent WNT signaling in basal-like breast cancer and brain metastasis. Carcinogenesis 32: 434-442, 2011.
31. Kao J, Salari K, Bocanegra M, et al: Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 4: e6146, 2009.
32. Lei X, Yang J, Nichols RW and Sun LZ: Abrogation of TGFbeta signaling induces apoptosis through the modulation of MAP kinase pathways in breast cancer cells. Exp Cell Res 313: 1687-1695, 2007.
33. Dumont N, Bakin AV and Arteaga CL: Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells. J Biol Chem 278: 3275-3285, 2003.
34. Anastas JN and Moon RT: WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13: 11-26, 2013.
35. Matsuda Y, Schlange T, Oakeley EJ, Boulay A and Hynes NE: WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth. Breast Cancer Res 11: R32, 2009.
36. Mathiasen IS, Sergeev IN, Bastholm L, Elling F, Norman AW and Jaattela M: Calcium and calpain as key mediators of apoptosis-like death induced by vitamin D compounds in breast cancer cells. J Biol Chem 277: 30738-30745, 2002.
37. Cui Y and Rohan TE: Vitamin D, calcium, and breast cancer risk: a review. Cancer Epidemiol Biomarkers Prev 15: 1427-1437, 2006.
38. Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA and Willett WC: Intake of dairy products, calcium, and vitamin d and risk of breast cancer. J Natl Cancer Inst 94: 1301-1311, 2002.
39. Benito E, Stiggelbout A, Bosch FX, et al: Nutritional factors in colorectal cancer risk: a case-control study in Majorca. Int J Cancer 49: 161-167, 1991.
40. Negri E, La Vecchia C, D'Avanzo B and Franceschi S: Calcium, dairy products, and colorectal cancer. Nutr Cancer 13: 255-262, 1990.
41. Lajer H and Daugaard G: Cisplatin and hypomagnesemia. Cancer Treat Rev 25: 47-58, 1999.
42. Wark PA, Lau R, Norat T and Kampman E: Magnesium intake and colorectal tumor risk: a case-control study and meta-analysis. Am J Clin Nutr 96: 622-631, 2012.
43. Maier JA, Nasulewicz-Goldeman A, Simonacci M, Boninsegna A, Mazur A and Wolf FI: Insights into the mechanisms involved in magnesium-dependent inhibition of primary tumor growth. Nutr Cancer 59: 192-198, 2007.
44. Dai Q, Shrubsole MJ, Ness RM, et al: The relation of magnesium and calcium intakes and a genetic polymorphism in the magnesium transporter to colorectal neoplasia risk. Am J Clin Nutr 86: 743-751, 2007.
45. Jang JY, Jeon YK and Kim CW: Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells. BMC Cancer 10: 391, 2010.
46. Kang JH, Song KH, Jeong KC, et al: Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells. BMC Cancer 11: 334, 2011.
47. Li Y and Sarkar FH: Gene expression profiles of genistein-treated PC3 prostate cancer cells. J Nutr 132: 3623-3631, 2002.
48. Suzuki A, Ozono K, Kubota T, Kondou H, Tachikawa K and Michigami T: PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3beta in osteoblastic Saos-2 cells. J Cell Biochem 104: 304-317, 2008.
49. Takeuchi E, Tanaka T, Umemoto E, et al: VLA-4-dependent and -independent pathways in cell contact-induced proinflammatory cytokine production by synovial nurse-like cells from rheumatoid arthritis patients. Arthritis Res 4: R10, 2002.